Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 72Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Non-Hodgkin 33Leukemia 33Burkitt Lymphoma 33Lymphoma, Mantle-Cell 20Lymphoma, Follicular 19Recurrence 13Lymphoma, B-Cell 13Hodgkin Disease 13Neoplasms 11Lymphoma, Large-Cell, Anaplastic 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Sarcoma 9Neuroblastoma 8Multiple Myeloma 8Medulloblastoma 8Lymphoma, T-Cell, Peripheral 8Lymphoma, T-Cell 7Central Nervous System Neoplasms 7Rhabdomyosarcoma 6Leukemia, Biphenotypic, Acute 6Lymphoma, B-Cell, Marginal Zone 5Wilms Tumor 4Waldenstrom Macroglobulinemia 4Sarcoma, Ewing 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

trametinib 1dabrafenib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ganglioneuroma × Vincristine × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡